Navigation Links
GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
Date:4/1/2009

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information please visit us.gsk.com

BOXED WARNING and Additional Important Safety Information for TYKERB

Hepatotoxicity - TYKERB has been associated with hepatotoxicity. Hepatotoxicity (ALT or AST >3 times the upper limit of normal and total bilirubin >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with TYKERB should be discontinued and patients should not be re-treated with TYKERB.

Decreased Left Ventricular Ejection Fraction - TYKERB has been reported to decrease LVEF. Caution should be taken if TYKERB is to be administered to patients with preexisting cardiac conditions, including uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. Confirm normal LVEF before starting TYKERB, and continue evaluations during treatment.

Patients with Severe Hepatic Impairment - If TYKERB is to be administered to patients with severe hepatic impairment, dose reduction should be considered.

Diarrhea - Diarrhea, including severe diarrhea, has been reported during treatment with TYKERB and was the most common adverse reaction resulting in discontinuation of TYKERB therapy. Proactive management of diarrhea w
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
2. Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
3. Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
4. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
5. STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter
6. TriServ Alliance Submits Final Bid for TRICARE South Region Contract
7. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
8. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
9. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
10. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
11. TriServ Alliance Submits Bid for TRICARE South Region Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... April 17, 2015 In Defense of ... following statement: “On Wednesday April 15th, the European Parliament ... a resolution recognizing the Armenian Genocide, “paying tribute, on ... the one-and-a-half million innocent Armenian victims who perished in ... extols the EU for this timely and needed recognition ...
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. Steven ... platelet-rich plasma (PRP) and stem cell therapy. ... for its world-class care of injury-caused and chronic joint ... in many other physicians offering regenerative medicines. , ... pain management and rehabilitation. Dr. Meier and MOSM can ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... that computerized prescription could be used to avoid medical mistakes, ... to even more errors. ,It is known that adverse ... hospitals each year. One way hospitals are trying to cut ... But according to a new study, use of computerized systems ...
... antihypertensive strategies that use calcium channel blockers and ... with beta-blockers and diuretics. ,Hypertensive patients either ... without the ACE inhibitor perindopril or the beta-blocker ... ,The trial ran for five years, but it ...
... common form of brain cancer might fare better with a ... ,Based on findings of the study it was seen ... glioblastoma receive surgery to remove as much of the cancer ... study compared 573 patients with glioblastomas who were randomized to ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
... people it was found that men who drank six cups ... 12 to 18 years, while women who drank that amount ... their study revealed an unequivocal evidence for an inverse and ... other risk factors. However researchers say the reasons for ...
... Switzerland it was seen that the frequency of withholding ... a patient’s life varies greatly among European countries. The ... in diagnostics and treatment to save and sustain life. ... patient’s life, physicians may refrain from using all possible ...
Cached Medicine News:
(Date:4/17/2015)... 17, 2015 Contego Medical, the first ... filter platform for angioplasty balloon and stent delivery ... Series B financing round led by Hatteras Venture ... focus on medical devices, biopharmaceuticals, diagnostics and related ... Mountain Group Partners, Lookout Capital and Medical Mutual. ...
(Date:4/17/2015)... NORTH CHICAGO, Ill. , April 17, 2015  AbbVie ... ABBV) today announced that it has extended the expiration of ... of common stock of Pharmacyclics, Inc. to 5 p.m., ... 2015. On April 17, 2015, AbbVie also ... Hart-Scott-Rodino Antitrust Improvements Act in order to provide the FTC ...
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
Breaking Medicine Technology:Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
... are packaged in easy open, single use, ... saturated with precisely the correct amount of ... saturated with a multi-purpose topical gel, for ... approved for venipuncture site preparation prior to ...
... Swabsticks are packaged in single-use ... Swabstick is saturated with precisely ... Each package is terminally sterilized, ... for the patient. Swabstick provides ...
Medicine Products: